SUMMARY Anti-acetylcholine receptor antibody titres have been monitored in the sera of 19 myasthenic patients treated with plasma exchange combined with a three month period of immunosuppressive therapy. In general the post-exchange titres stabilised at below pre-exchange levels for prolonged periods which were associated with clinical improvement. In seven instances recurrence of symptoms occurred and in six of these cases relapse was shown to be associated with a rise in anti-acetylcholine receptor antibody titre.
Myasthenia gravis is now generally accepted to be an autoimmune disease in which circulating antibodies specific for the acetylcholine receptor (AChR) play an important role.' Plasma exchange has been successfully used in the treatment of Goodpasture's syndrome,2 an autoimmune disease in which antibodies are formed against glomerular and pulmonary basement membranes3 and reports have appeared of its application to myasthenic patients.4-7 These papers describe the results of plasma-exchange used in conjunction with immunosuppressive therapy in the treatment of limited numbers (maximum seven) of myasthenic patients, and serial assays of circulating antiAChR antibodies over periods of up to 12 months are reported.7 Nineteen myasthenic patients have now been treated by plasma-exchange in combination with a three month period of immunosuppression and the details of their clinical condition throughout an 18 month follow-up period have been reported. 8 The anti-AChR antibody titres of these patients were assayed over the same period and these results are discussed in the present paper.
Patients and methods
Patients Nineteen patients with undisputed myasthenia gravis were studied. All patients had the disease confirmed by a classical clinical history, demonstrable fatiguable weakness, a positive response to edrophonium hydrochloride and a decrementing response to repetitive supramaximal nerve stimulation. There were 12 females and seven males, whose ages ranged from 26 to 75 with a mean of 51 years. Seventeen patients had the generalised form of the disease, whilst two had only the eye muscles clinically affected. Myasthenia had been present from 2-29 years with a mean duration of 10 years. Sixteen patients had had a thymectomy previously.
All patients were on anticholinesterase therapy. Five were also on steroids (30-60 mg prednisolone per day) prior to plasma exchange, and three of these five patients had received, in the preceding six months, a three-month course Following a series of plasma exchanges, the anti-AChR antibody titres remained below preexchange levels for the total period of postexchange observation (between 6 and 18 months) in 13 out of the 18 patients followed. One patient (case 1) died 4 months after completion of exchange.8 In these cases the general pattern was that of a sharp rise in titre during the first month after a series of exchanges followed by a gradual fall and stabilisation of titres over the ensuing months (fig 1) . Of the five patients (cases 3, 5, 11, 17, 19) who showed elevated post-exchange antiAChR antibody titres (that is above pre-exchange levels), three (cases 3, 17, 19) suffered a recurrence of myasthenic symptoms coincident with their elevated titres (fig 1(b) (e) ). In addition four further patients (cases 6, 7, 9, 14) underwent relapses. In three of these (cases 6, 7, 14) the recurrence of symptoms was also associated with a peak of anti-AChR-antibody titre although in these cases pre-exchange levels were not surpassed. The remaining patient (case 9) suffered two relapses (fig 1(b) ) which were not shown to coincide with elevated titres.
It is noteworthy that of the three patients with thymoma, all had relatively high preexchange anti-AChR antibody titres and two (cases 9 and 14) Our observation of elevated anti-AChR antibody titres in all the myasthenic patients described in this paper is consistent with previous figures of around 90% 10 11 obtained from large samples of myasthenics in a range of clinical states. Although correlation of antibody titre with severity of disease is generally poor,'1 12 it is true that the clinical state of a given patient is often reflected in his anti-AChR titre over a period of time" and the patients chosen for plasmaexchange contain many whose clinical condition, in spite of conventional treatment, has continued to deteriorate. The probability of elevated titres in these patients might accordingly be expected to be somewhat higher than that of a random sample.
The lack of good correlation between antiAChR antibody titre and clinical state across a range of patients is well illustrated by the present data. Thus the pre-exchange titres range from 0 8 to 284 x 10-10 M a-bungarotoxin-binding sites of which one of the highest (205 x 10-10 M sites) was shown by a patient (case 4) with relatively good physical performance (table) whereas a pre-exchange titre of only 2-8 x 10-10 M a-bungarotoxin binding sites was obtained from one (case 3) of the four patients confined to a respirator.
The pattern of anti-AChR antibody titres shown in fig 2 is typical of that obtained 
